Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Baseline PET-CT in predicting CRS and survival outcomes of R/R MM patients following CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

YLY LiYHYongxian Hu

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows PET-CT predicts survival outcomes in R/R MM patients, indicating risks of CRS and treatment implications.

Key Points

  • To assess the predictive capabilities of PET-CT in evaluating CRS and survival outcomes in R/R MM patients after CAR T-cell therapy.
  • Retrospective study of 62 patients with R/R MM receiving BCMA CAR T-cell therapies.
  • Logistic regression analyses to evaluate metabolic tumor volume (MTV) and total lesion glycolysis (TLG) for predicting severe CRS.
  • Kaplan-Meier and multivariate Cox regression analyses to assess survival outcomes.
  • High MTV (>107.2 cm3) and high TLG (>406.5) are risk factors for severe CRS.
  • Patients with low MTV or TLG showed superior progression-free survival (PFS).
  • Low TLG predicted better long-term overall survival (OS) compared to low MTV.

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d687https://doi.org/10.1182/blood-2025-5855
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Validated PET-CT metabolic tumor volume threshold identifies high-risk relapsed/refractory LBCL and predicts 12-month toxicity-free progression-free survival Post–CAR-T therapy2025
  2. 2Prognostic value of positron emission tomography-derived metabolic tumor volume for the efficacy of anti-CD19 CAR T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphomas2025
  3. 3Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.2026
  4. 4B07 | PROGNOSTIC ROLE OF STANDARDIZED (18)F-FDG-PET/CT AND WB-DW-MRI IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING T CELL-REDIRECTING THERAPIES2026
  5. 5Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy2026 · 1 citations